4574
TAIKO PHARMACEUTICAL CO.,LTD.
大幸薬品
- Industry
- Pharmaceutical
- Market
- Prime
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Dec 2021
11,299
Dec 2022
5,040
Dec 2023
6,120
Dec 2024
6,292
Dec 2025
6,397
Operating profit(million JPY)
Dec 2021
-4,947
Dec 2022
-3,079
Dec 2023
-1,005
Dec 2024
629
Dec 2025
459
Operating profit margin(%)
Dec 2021
-43.78
Dec 2022
-61.09
Dec 2023
-16.42
Dec 2024
10
Dec 2025
7.18
Profit before tax(million JPY)
Dec 2021
-8,887
Dec 2022
-4,869
Dec 2023
-3,563
Dec 2024
565
Dec 2025
958
Profit(million JPY)
Dec 2021
-9,594
Dec 2022
-4,895
Dec 2023
-3,611
Dec 2024
898
Dec 2025
923
Total assets(million JPY)
Dec 2021
22,535
Dec 2022
15,046
Dec 2023
13,220
Dec 2024
12,914
Dec 2025
12,270
Cash and cash equivalents(million JPY)
Dec 2021
5,521
Dec 2022
2,797
Dec 2023
5,244
Dec 2024
4,532
Dec 2025
4,256
Cash flows from operating activities(million JPY)
Dec 2021
-1,595
Dec 2022
-1,994
Dec 2023
-307
Dec 2024
362
Dec 2025
814
Cash flows from investing activities(million JPY)
Dec 2021
-1,622
Dec 2022
190
Dec 2023
1,166
Dec 2024
-5
Dec 2025
142
Cash flows from financing activities(million JPY)
Dec 2021
3,959
Dec 2022
-997
Dec 2023
1,539
Dec 2024
-1,181
Dec 2025
-1,227
Return on equity(%)
Dec 2021
-53.9
Dec 2022
-47
Dec 2023
-48.9
Dec 2024
12.2
Dec 2025
11.2
Equity ratio(%)
Dec 2021
56.8
Dec 2022
53.5
Dec 2023
51
Dec 2024
61.7
Dec 2025
69.4
Earnings per share(JPY per share)
Dec 2021
-220.52
Dec 2022
-112.26
Dec 2023
-76.25
Dec 2024
17.9
Dec 2025
18.38
Net assets per share(JPY per share)
Dec 2021
293.88
Dec 2022
184.6
Dec 2023
134.93
Dec 2024
158.67
Dec 2025
169.51
Dividend per share(JPY per share)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
3.3
Payout ratio(%)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
17.95
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.